Early efficacy of stereotactic body radiation therapy combined with adoptive immunotherapy for advanced malignancies

Wang,Yi-Shan; Yang,Guiqing; Wang,Yuan-Yuan; Yang,Jia-Lin; Yang,Ke

doi:10.3892/mco.2013.157

Early efficacy of stereotactic body radiation therapy combined with adoptive immunotherapy for advanced malignancies

Authors:
- Yi-Shan Wang
- Guiqing Yang
- Yuan-Yuan Wang
- Jia-Lin Yang
- Ke Yang
View Affiliations

Affiliations: Center for Tumor Treatment, People's Liberation Army 107th Hospital, Yantai, Shandong 264003, P.R. China
Published online on: July 23, 2013 https://doi.org/10.3892/mco.2013.157
Pages: 925-929

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stereotactic body radiation therapy (SBRT) concentrates radiation to a predefined target, affecting all the cells within it. Adoptive immunotherapy is not restricted by the major histocompatibility complex (MHC) in recognizing and eliminating target cells. We investigated the effects of the combined modality of SBRT and adoptive immunotherapy on patients with advanced malignant tumors. the database of 316 patients with 845 tumors who underwent SBRT between April, 2010 and February, 2012 was retrospectively reviewed. Of the 316 patients, 145 received biological immunotherapy and were assigned into the observation group, whereas the remaining patients constituted the control group. Patients in the two groups were recorded on efficacy assessment, Karnofsky performance status (KPS), cell phenotype expression level in vitro and the percentages of lymphocyte subsets and ratio of CD4+̸CD8+ lymphocytes in the peripheral blood. Following treatment, the total effectiveness [complete response (CR) + partial response (PR)], the KPS score, the percentages of lymphocyte subsets and the CD4+̸CD8+ lymphocyte ratio in the observation group were higher compared to those in the control group, with a statistically significant difference (P<0.05). The expression of CD3+ and CD3+CD56+ cytokine‑induced killer (CIK) cells were increased from 56.76±4.54% and 11.32±2.96% to 94.67±4.46% and 32.65±1.12%, respectively, when cultured in vitro (P<0.01). The percentages of lymphocyte subsets and the CD4+̸CD8+ lymphocyte ratio were signiﬁcantly increased compared to prior to treatment in the observation group (P<0.05). SBRT combined with adoptive immunotherapy may be a novel therapeutic option for patients with advanced malignant tumors.

View Figures

View References

1	Linn YC and Hui KM: Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010:4357452010.PubMed/NCBI
2	Yamazaki H, Shiomi H, Tsubokura T, Kodani N, Nishimura T, Aibe N, Udono H, Nishikata M, Baba Y, Ogita M, Yamashita K and Kotsuma T: Quantitative assessment of inter-observer variability in target volume delineation on stereotactic radiotherapy treatment for pituitary adenoma and meningioma near optic tract. Radiat Oncol. 6:102011.
3	Wang YS, Wang YY, Jiang P, Ma JJ, Qu Z, Wang XL, Li JT and Jia XF: Short-term outcomes of CyberKnife therapy for advanced high-risk tumors: A report of 160 cases. Exp Ther Med. 3:725–727. 2012.PubMed/NCBI
4	Wang CC, Floyd SR, Chang CH, Warnke PC, Chio CC, Kasper EM, Mahadevan A, Wong ET and Chen CC: Cyberknife hypofractionated stereotactic radiosurgery (HSRS) of resection cavity after excision of large cerebral metastasis: efficacy and safety of an 800 cGy × 3 daily fractions regimen. J Neurooncol. 106:601–610. 2012.PubMed/NCBI
5	Verneris MR, Baker J, Edinger M and Negrin RS: Studies of ex vivo activated and expanded CD8⁺NK-T cells in humans and mice. J Clin Immunol. 22:131–136. 2002. View Article : Google Scholar : PubMed/NCBI
6	Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissmen IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar
7	Schmidt-Wolf GD, Negrin RS and Schmidt-Wolf IG: Activated T cells and cytokine-induced CD3⁺CD56⁺killer cells. Ann Hematol. 74:51–56. 1997. View Article : Google Scholar : PubMed/NCBI
8	Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL and Negrin RS: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
9	Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, Karimi M and Negrin RS: In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 112:2563–2574. 2008. View Article : Google Scholar : PubMed/NCBI
10	Wang X, Wang YY, Jiang P, Ma JJ, Qu Z, Liu HC, Wang SS and Wang YS: Clinical application of CyberKnife for high-risk central nervous system tumors: A clinical trial report of 60 cases. Exp Ther Med. 3:105–108. 2012.PubMed/NCBI
11	Rutkowski MJ, Bloch O, Jian BJ, Chen C, Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW and Parsa AT: Management of recurrent intracranial hemangiopericytoma. J Clin Neurosci. 18:1500–1504. 2011. View Article : Google Scholar
12	Cengiz M, Özyiğit G, Yazici G, Doğan A, Yildiz F, Zorlu F, Gürkaynak M, Gullu IH, Hosal S and Akyol F: Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys. 81:104–109. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS, Lee K, Park SK, Jeong YJ, Kim JM, Han G, Yang KH, Kim YJ, Kim Y and Han SB: Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol. 7:1793–1801. 2007. View Article : Google Scholar : PubMed/NCBI
14	Gütgemann S, Frank S, Strehl J and Schmidt-Wolf IG: Cytokine-induced killer cells are type II natural killer T cells. Ger Med Sci. 5:Doc072007.PubMed/NCBI
15	Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, Li YQ, Chen SP, Wu PH and Xia JC: Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother. 31:63–71. 2008. View Article : Google Scholar
16	Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P and Iacone A: Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol. 27:130–139. 2009. View Article : Google Scholar : PubMed/NCBI
17	Maluf PJ, Michelin MA, Etchebehere RM, Adad SJ and Murta EF: T lymphocytes (CD3) may participate in the recurrence of cervical intraepithelial neoplasia grade III. Arch Gynecol Obstet. 278:525–530. 2008. View Article : Google Scholar : PubMed/NCBI
18	Steffens HP, Kurz S, Holtappels R and Reddehase MJ: Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol. 72:1797–1804. 1998.
19	Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM and Hengartner H: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 369:31–37. 1994.PubMed/NCBI